ARA-290

ARA-290 is an engineered peptide based on erythropoietin (EPO), developed to investigate tissue-protective signaling separately from EPO's role in red blood cell formation. Research topics described in the supplied material include peripheral nerve dysfunction, inflammatory processes, and immune responses.

EPO is associated primarily with the regulation of red blood cell formation, but the supplied guide also discusses its potential roles in neuronal protection and inflammation. ARA-290 is presented as an attempt to retain selected tissue-related signaling properties without reproducing EPO's blood-cell-stimulating activity.

The guide attributes ARA-290's proposed activity to a receptor system involved in endogenous tissue repair. It also discusses possible effects on pain signaling and immune activity, although the notes do not establish how these mechanisms translate into clinical outcomes.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents ARA-290 as an EPO-based research compound intended to separate tissue-protective effects from stimulation of red blood cell formation. It identifies small-fiber nerve disorders, persistent inflammation, and autoimmune conditions as potential areas of investigation. The guide also characterizes clinical tolerability favorably, but the supplied notes contain no study references or methodological details supporting that assessment.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The strength, reproducibility, and clinical relevance of the reported effects cannot be determined from these notes alone. The receptor terminology and broad claims concerning autoimmune conditions require verification against primary research.

Safety data are limited, and the guide's favorable tolerability description does not establish an absence of adverse effects. Reduced stimulation of red blood cell formation would not, by itself, demonstrate overall safety or exclude other risks. This summary is educational and is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “ARA-290 small fiber neuropathy clinical trial”
• “ARA-290 neuroprotective effects”
• “Efficacy of ARA-290 in immune modulation”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN